Orser Capital Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,680
| Closed | -$2.71M | – | 55 |
|
|
2025
Q4 | $2.71M | Buy |
4,680
+1,455
| +45% | +$823K | 1.53% | 21 |
|
|
2025
Q3 | $1.56M | Hold |
3,225
| – | – | 0.82% | 34 |
|
|
2025
Q2 | $1.31M | Sell |
3,225
-200
| -6% | -$83.6K | 0.93% | 30 |
|
|
2025
Q1 | $1.7M | Sell |
3,425
-260
| -7% | -$141K | 1.25% | 25 |
|
|
2024
Q4 | $1.92M | Hold |
3,685
| – | – | 1.32% | 21 |
|
|
2024
Q3 | $2.28M | Sell |
3,685
-10
| -0.3% | -$5.92K | 1.63% | 19 |
|
|
2024
Q2 | $2.04M | Hold |
3,695
| – | – | 1.54% | 20 |
|
|
2024
Q1 | $2.15M | Sell |
3,695
-8
| -0.2% | -$4.49K | 2.01% | 20 |
|
|
2023
Q4 | $1.97M | Sell |
3,703
-4,811
| -57% | -$2.33M | 2.14% | 16 |
|
|
2023
Q3 | $4.31M | Sell |
8,514
-50
| -0.6% | -$26.6K | 4.26% | 6 |
|
|
2023
Q2 | $4.47M | Buy |
8,564
+505
| +6% | +$273K | 4.46% | 5 |
|
|
2023
Q1 | $4.64M | Buy |
8,059
+280
| +4% | +$158K | 5.24% | 4 |
|
|
2022
Q4 | $4.28M | Hold |
7,779
| – | – | 6.18% | 3 |
|
|
2022
Q3 | $3.94M | Sell |
7,779
-290
| -4% | -$162K | 7.01% | 3 |
|
|
2022
Q2 | $4.38M | Sell |
8,069
-496
| -6% | -$273K | 5.69% | 2 |
|
|
2022
Q1 | $5.06M | Sell |
8,565
-357
| -4% | -$205K | 3.09% | 5 |
|
|
2021
Q4 | $5.95M | Sell |
8,922
-420
| -4% | -$262K | 3.01% | 4 |
|
|
2021
Q3 | $5.34M | Buy |
9,342
+252
| +3% | +$138K | 2.94% | 5 |
|
|
2021
Q2 | $4.59M | Buy |
9,090
+60
| +0.7% | +$28.3K | 2.36% | 9 |
|
|
2021
Q1 | $4.12M | Sell |
9,030
-595
| -6% | -$284K | 2.68% | 9 |
|
|
2020
Q4 | $4.48M | Sell |
9,625
-346
| -3% | -$162K | 2.84% | 8 |
|
|
2020
Q3 | $4.4M | Sell |
9,971
-114
| -1% | -$47.1K | 3.48% | 4 |
|
|
2020
Q2 | $3.65M | Sell |
10,085
-711
| -7% | -$238K | 3.31% | 9 |
|
|
2020
Q1 | $3.06M | Sell |
10,796
-790
| -7% | -$249K | 4.31% | 4 |
|
|
2019
Q4 | $3.77M | Buy |
11,586
+406
| +4% | +$123K | 3.65% | 4 |
|
|
2019
Q3 | $3.15M | Buy |
11,180
+199
| +2% | +$57K | 3.69% | 4 |
|
|
2019
Q2 | $3.35M | Sell |
10,981
-421
| -4% | -$116K | 3.46% | 4 |
|
|
2019
Q1 | $3.12M | Buy |
11,402
+3,101
| +37% | +$772K | 3.43% | 3 |
|
|
2018
Q4 | $1.91M | Hold |
8,301
| – | – | 2.2% | 16 |
|
|
2018
Q3 | $1.91M | Sell |
8,301
-570
| -6% | -$131K | 1.83% | 17 |
|
|
2018
Q2 | $1.88M | Sell |
8,871
-391
| -4% | -$83K | 1.63% | 20 |
|
|
2018
Q1 | $1.94M | Buy |
9,262
+131
| +1% | +$27.5K | 1.79% | 16 |
|
|
2017
Q4 | $1.91M | Buy |
+9,131
| New | +$1.75M | 1.7% | 17 |
|
Other funds holding TMO
VCM
Orser Capital Management's TMO Position: Q1 2026 in Review
Orser Capital Management sold out of Thermo Fisher Scientific (TMO) in Q1 2026, closing a stake of 4,680 shares — an estimated $2.71M sold.
Orser Capital Management first reported a position in TMO in Q4 2017 and held it in 33 quarters. The position peaked at $5.95M in Q4 2021. 2,590 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Orser Capital Management reported no remaining Thermo Fisher Scientific position as of Q1 2026 after selling out during the quarter.
- Orser Capital Management sold 4,680 Thermo Fisher Scientific shares in Q1 2026, an estimated $2.71M.
- Orser Capital Management first reported a position in Thermo Fisher Scientific in Q4 2017 and held it in 33 quarters.
- Orser Capital Management's Thermo Fisher Scientific position peaked at $5.95M in Q4 2021.
- 2,590 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Orser Capital Management's 13F filing for Q1 2026, filed 16 Apr 2026.